SCHEMBL5563952

SCHEMBL5563952

c1coc(-n2ncc3ccccc32)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 1/20 0.42
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
MGAM O43451 1/20 0.39
GAA P10253 1/20 0.39
SI P14410 1/20 0.39
MGAM2 Q2M2H8 1/20 0.39
RECQL P46063 1/20 0.39
MKNK1 Q9BUB5 2/20 0.36
MKNK2 Q9HBH9 2/20 0.36
MAPK8 P45983 1/20 0.36
MAPK9 P45984 1/20 0.36
MAPK10 P53779 1/20 0.36
PDE10A Q9Y233 7/20 0.36
CYP1A2 P05177 2/20 0.36
CCNT1 O60563 2/20 0.35
CDK1 P06493 2/20 0.35
CCNB1 P14635 2/20 0.35
CDK9 P50750 2/20 0.35
CDK7 P50613 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5782995 0.77 MAPK8 (0.43) CYP11B1CYP11B2MAPK8MAPK10KDM4E
SCHEMBL6797544 0.72 LRRK2 (0.46) LRRK2CYP11B1CYP11B2MGAMGAA
SCHEMBL5565427 0.71 CYP11B1 (0.40) LRRK2CYP11B1CYP11B2MGAMGAA
SCHEMBL13052911 0.71 CYP11B2 (0.55) LRRK2CYP11B1CYP11B2MGAMGAA
SCHEMBL729956 0.71 KDM4E (0.56) LRRK2CYP11B1CYP11B2MGAMGAA
SCHEMBL30270004 0.71 KDM4E (0.56) LRRK2CYP11B1CYP11B2MGAMGAA
SCHEMBL22345403 0.70 LRRK2 (0.44) LRRK2CYP11B1CYP11B2MGAMGAA
Hydrochloric Acid SCHEMBL3379409 0.69 KDM4E (0.55) LRRK2CYP11B1CYP11B2MGAMGAA
SCHEMBL12075159 0.69 MKNK1 (0.46) LRRK2CYP11B1CYP11B2MGAMGAA
SCHEMBL6086456 0.69 ALDH1A1 (0.34) MAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7226941-B2 Compound for treating angiogenesis HIF BIO, INC. (US) 2007-06-05 US disclosed
EP-1646382-A2 COMPOUNDS, COMPOSITIONS AND METHODS HIF BIO INC. (US) 2006-04-19 EP disclosed
US-20050187276-A1 Compounds, compositions and methods BIZBIOTECH CO., LTD. (KR) 2005-08-25 US disclosed
WO-2005030121-A2 COMPOUNDS, COMPOSITIONS AND METHODS HIF BIO, INC. (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187276-A1 Compounds, compositions and methods HIF1A, HIF1AN, EGLN3 LRRK2 3734/4885CYP11B1 402/4885CYP11B2 564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.